ArticleBritish journal of clinical pharmacology2015
Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control study.
Article in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Statins associate with lower risk of biliary tract cancers: A systematic review and meta-analysis.Cancer medicine · 2023Pooled it
- Statins intake and risk of liver cancer: A dose-response meta analysis of prospective cohort studies.Medicine · 2017Pooled it
- Meta-analysis of studies using statins as a reducer for primary liver cancer risk.Scientific reports · 2016Pooled it
- Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026Review
- Lipid Metabolism Reprogramming in Tumor-Associated Macrophages Modulates Their Function in Primary Liver Cancers.Cancers · 2025Review
- Risk Factors and Prevention of Cancer and CVDs: A Chicken and Egg Situation.Journal of clinical medicine · 2025Review
- Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.EMBO molecular medicine · 2024Article
- Review
- Viral hepatitis increases the risk of cholangiocarcinoma: a systematic review and meta-analysis.Translational cancer research · 2023Article
- Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers.Frontiers in oncology · 2022Review
- Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.International journal of molecular sciences · 2020Article
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Nature reviews. Gastroenterology & hepatology · 2020Review
- Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink.Gut · 2019Article
- Association between metabolic syndrome and hepatobiliary cancers: A case-control study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019Article
- Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study.Frontiers in pharmacology · 2019Article
- Syncope and Collapse Are Associated with an Increased Risk of Cardiovascular Disease and Mortality in Patients Undergoing Dialysis.International journal of environmental research and public health · 2018Observational
- Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis.Biomedical reports · 2018Article
- Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHAOncotarget · 2018Article
- Aspirin use is associated with a reduced risk of cholangiocarcinoma: a systematic review and meta-analysis.Cancer management and research · 2018Article
- Association Between Cholangiocarcinoma and Proton Pump Inhibitors Use: A Nested Case-Control Study.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsCholangiocarcinoma (CCA) is the second most common primary liver cancer in the world. Due to the lack of effective treatments, the survival rate of CCA is low and it is usually considered difficult to diagnose early. To date, no effective strategies for the prevention of CCA have been developed. Statins are cholesterol-lowering agents which possess pleiotropic properties and the use of statins may reduce cancer risk. The aim of the study was to investigate the effect of statin use on the risk of CCA.
methodsWe used nationwide insurance data to perform a case-control study including 3174 CCA patients diagnosed in 2002-2011 and 3174 propensity score matched controls. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated to assess the association between CCA risk and statin use by type of statin and dose.
resultsPatients with CCA were slightly younger than controls with mean ages of 67.4 (SD 12.3) and 68.5 (SD 13.2) years (P = 0.001), respectively, and had less users of statins (22.7 vs. 26.5%, P < 0.001). The overall adjusted OR of statin use associated CCA was 0.80 (95% CI 0.71, 0.90) and lowered for those with longer medications. The OR ranged from 0.65 to 0.77. Stronger dose-response association was seen when using lovastatin.
conclusionsStatin use is associated with reduced risk of CCA and there is a dose-response relationship between the use of statins and risk of CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.